Compare KRNT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | DBVT |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | Israel | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.3M | 508.8M |
| IPO Year | 2015 | N/A |
| Metric | KRNT | DBVT |
|---|---|---|
| Price | $13.90 | $18.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $19.75 | $19.04 |
| AVG Volume (30 Days) | ★ 467.7K | 452.4K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,041,000.00 | $5,502,000.00 |
| Revenue This Year | $3.86 | $1,768.71 |
| Revenue Next Year | $2.57 | $1,028.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.17 | N/A |
| 52 Week Low | $11.93 | $2.74 |
| 52 Week High | $34.29 | $21.50 |
| Indicator | KRNT | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 71.05 |
| Support Level | $13.70 | $12.75 |
| Resistance Level | $14.63 | $21.50 |
| Average True Range (ATR) | 0.46 | 1.17 |
| MACD | 0.13 | 0.70 |
| Stochastic Oscillator | 63.65 | 68.34 |
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.